Prot #DCC-2036-01-003: An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors

Project: Research project

Project Details

StatusActive
Effective start/end date9/6/199/6/22

Funding

  • Deciphera Pharmaceuticals, LLC (Prot #DCC-2036-01-003)